Colon, Rectum Cancer Colorectal
Conditions
Interventions
1. Group A: Intravenous ranitidine, 100 mg, administered twice daily for 5 days or until oral treatment is tolerated, followed by oral ranitidine, 150 mg twice daily until death or for a period of 5 y
Sponsors
Glaxo Wellcome (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged >18 years 2. Diagnosis of colorectal cancer 3. This is the first operation for cancer and the life expectancy of the patient is at least 3 months at the time of surgery 4. No concurrent chronic modulating therapy with systemic steroids, antiviral agents or other known immunomodulating drugs 5. No systemic antimicrobial agents in the 48 h prior to entry into the study 6. Not currently or planning to undergo chemotherapy, radiotherapy or any other therapy for cancer 7. No medical contraindications to protocol treatments
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed